NEUROENDOCRINE MODULATORS AND ISCHEMIC STROKE
The stroke field is a relatively new avenue for the Ashpole laboratory. We previously found that reducing IGF-1R in astrocytes alters their ability to uptake glutamate, a major contributor to ongoing stroke damage. Furthermore, there is a significant amount of evidence showing that low IGF-1 is associated with poor stroke outcomes and increased mortality. In our literature review (currently under review), we highlight evidence in preclinical models that show administering exogenous IGF-1 in the hours surrounding stroke attenuates neurological deficits and improves behavioral outcomes. Thus, we aim to understand the underlying cellular mechanisms involved in the previously observed protection from administering IGF-1 in stroke models. This project is currently ongoing, so subscribe for updates!
This project is currently funded by the University of Mississippi Graduate Research Counsel Grant.
Transgenic Mouse Models
Middle Cerebral Artery Occlusion
Sensorimotor Behavioral Test